𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Structure guided P1′ modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer’s disease

✍ Scribed by Holger Monenschein; Daniel B. Horne; Michael D. Bartberger; Stephen A. Hitchcock; Thomas T. Nguyen; Vinod F. Patel; Lewis D. Pennington; Wenge Zhong

Book ID
113496882
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
887 KB
Volume
22
Category
Article
ISSN
0960-894X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Boom in the development of non-peptidic
Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease
✍ Romano Silvestri 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

## Abstract β‐Amyloid cleaving enzyme‐1 (BACE1) has become a significant target for the therapy of Alzheimer's disease. After the discovery of the first non‐peptidomimetic β‐secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non‐

β-secretase as a target for the treatmen
β-secretase as a target for the treatment of Alzheimer's disease
✍ Martin Citron 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 1 views

## Abstract Finding inhibitors of the first step of the amyloid cascade, Aβ~42~ generation, is a major goal of Alzheimer's disease drug development. Two target protease activities, β‐and γ‐secretase, were detected more than 10 years ago but progress in this area has been slow because the enzymes we